Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Frontiers in Cellular and Infection Microbiology|October 30, 2023
Screening of the novel antimicrobial drug, XF-73, against 2,527 <i>Staphylococcus</i> species clinical isolatesWilliam Rhys-Williams, Helen Marie Galvin, William Guy LoveInternational Journal of Antimicrobial Agents|March 30, 2010
In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial speciesDavid J Farrell, Marion Robbins, William Rhys-Williams, et al.Antimicrobial Agents and Chemotherapy|December 15, 2010
Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage studyDavid J Farrell, Marion Robbins, William Rhys-Williams, et al.The Journal of Antimicrobial Chemotherapy|August 20, 2009
XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activityNicola Ooi, Keith Miller, Joanne Hobbs, et al.International Journal of Antimicrobial Agents|March 19, 2011
Extracellular and intracellular bactericidal activities of XF-70 against small-colony variant hemB mutants of meticillin-susceptible and meticillin-resistant Staphylococcus aureusPierre Vaudaux, Elzbieta Huggler, William Rhys-Williams, et al.The Journal of Antimicrobial Chemotherapy|November 6, 2009
XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilmsNicola Ooi, Keith Miller, Christopher Randall, et al.Frontiers in Cellular and Infection Microbiology|July 18, 2022
Antibacterial and Antibiofilm Potency of XF Drugs, Impact of Photodynamic Activation and Synergy With AntibioticsEmma Louise Board-Davies, William Rhys-Williams, Daniel Hynes, et al.Journal of the Royal Society, Interface|July 20, 2006
Calcium-binding phospholipids as a coating material for implant osteointegrationMatteo Santin, William Rhys-Williams, Josephine O'Reilly, et al.Infection Control and Hospital Epidemiology|October 10, 2024
Exeporfinium chloride (XF-73) nasal gel significantly reduces <i>Staphylococcus aureus</i> nasal carriage in cardiac surgery patients throughout surgery and the early recovery period: results from a randomized placebo-controlled Phase 2 studyJulie E Mangino, Michael S Firstenberg, William Rhys-Williams, et al.Infection Control and Hospital Epidemiology|March 23, 2023
Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced <i>Staphylococcus aureus</i> nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 studyJulie E Mangino, Michael S Firstenberg, Rita K C Milewski, et al.Pageof 2